Watson Pharmaceuticals,Inc., a specialty pharmaceutical company, announced todaythat its subsidiary Watson Laboratories, Inc. has reached a settlement withBarr Laboratories, Inc. on outstanding patent litigation related to Watson’sOxytrol@ (Oxybutynin Transdermal System, 3.9mg/24hr.) product.On August 19, 2008, Barr submitted an Abbreviated New Drug Application(ANDA) seeking approval to market a generic version of Oxytrol. Under termsof the settlement agreement, Watson has granted Barr a royalty-bearing licenseto the U.S. patents covering Oxytrol to commence marketing a genericequivalent product on April 26, 2015, or earlier in certain circumstances.
Related Articles Read More >
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
Eicos Sciences’ FDA-approved Aurlumyn promises to drastically reduce frostbite amputations
